A Phase 3 Randomized Open-Label Three Arm Study of PF-06801591 in Combination with BCG (Induction With or Without Maintenance) Versus BCG (Induction and Maintenance) in Participants with HR BCG-Na ve NMIBC (B8011006)
Brief description of study
The purpose of the study is to determine the safety and efficacy of PF-06801591 (an anti-PD-1 antibody) combined with Bacillus Calmette- Guerin (BCG) in patients with high-risk, BCG-naïve Non-Muscle Invasive Bladder Cancer (NMIBC). We want to know if the combined treatment of PF-06801591 and Bacillus Calmette- Guerin (BCG) works better than BCG alone.
Clinical Study Identifier: s19-01432
ClinicalTrials.gov Identifier: NCT04165317
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
